SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more

Jan 16, 2025
1 min read

He highlights the company's current clinical programs, and talks about how thy are leveraging for the future the unique expertise in muscle biology Cytokinetics has built over three decades.

https://vimeo.com/1047679397

Recent Posts

See All

Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point

Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - the company believes it has its own best in class insulin leveraging this

Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity

SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight